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Problem: Currently used standard treatments (Chemotherapy, radiation) in cancer 
patients are generally accompanied with side effects, which may include pain, nausea, 
vomiting, fatigue, and chemotherapy-induced peripheral neuropathy (CIPN) during and 
after completion of treatments. High dose IV C may improve the anti-cancer action of 
chemotherapeutic agents by reducing side effects of fatigue, pain, nausea and vomiting 
and boosting immune cell functioning, and inhibiting angiogenesis (Mikirova, Casciari, 
& Hunninghake, 2019).The purpose of this quality improvement project was to explore 
whether high dose intravenous vitamin C (IV C) prevented major side effects that 
frequently occur with standard treatments in cancer patients and measure quality of life. 
Methods: An observational, descriptive, cohort study utilizing a retrospective medical 
record review. A Plan-do-study-act (PDSA) cycle was utilized to evaluate the 
effectiveness of IV C in cancer patients. 
Results: A total number of twenty (N=20) charts of participants who received IV C 
therapy for different types of cancer were reviewed. There were fourteen females (N=14, 
70%) and six males (N=6, 30%) who underwent the therapy. Seven (N=7, 35%) of the 
patients received IV C/Traditional and thirteen (N=13, 65%) received IV C only. None of 
the participants reported any side/adverse effects to IV C and all reported improved 
quality of life. 
Implications: There were little to no side/adverse effects noted to this study, therefore IV 
C could be an appropriate alternative or adjunct therapy to treat cancer patients. 
Monitoring these patients for a longer period of time may yield more beneficial results 
and improved quality of life. 
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Millions of people continue to be diagnosed and live with cancer which is the 
second most prevalent terminal disease around the world today (American Cancer 
Society, [ACS], 2019). Statistics show that, lung, breast, and prostate cancer top the chart 
for the highest mortality rate (ACS, 2019). Lung cancer has the highest mortality of 56% 
for a five-year survival rate (Siegel, Miller & Jemal, 2018). Lung cancer has 228,820 new 
cases and 135,720 deaths were estimated in 2020; there were 279,100 new cases of breast 
cancer which is the most prevalent cancer in women in the US with 42,690 deaths 
recorded to date. Prostate cancer has a total number of 191,930 new cases and 33,330 
deaths to date in the US (ACS, 2019).  
It is estimated that between 19% to over 85% of cancer patients are affected by 
antineoplastic agents, causing chemotherapy induced peripheral neuropathy (CIPN) and 
leading to motor and autonomic damage to the body which gradually unfolds over the 
years after treatment (Zajączkowska, Kocot-Kępska, Leppert, Wrzosek, Mika, 
Wordliczek, 2019). Cancer patients undergo major side effects including pain, fatigue, 
nausea, and vomiting which are very common when treated with traditional/conventional 
treatments. The use of high dose IV C for cancer patients has been used for many decades 
by complimentary alternative medicine (CAM) providers with few side effects reported. 
Statistics show that out of the 9,328 patients surveyed, only 1% reported minor side 
effects (Carr & Cook, 2018). 
In 2012, there were 14.1 million new cases and 8.2 million cancer-related deaths 
worldwide. In the year 2019, 57% of new cancer cases occurred in less developed regions 
of the world. These include Central America, Asia, and parts of Africa.  
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Statistics show that 65% of deaths are due to cancer. The number of new cancer cases per 
year is expected to rise to 23.6 million by 2030 globally (ACS, 2019).  
 Statistics from the (Centers for Disease Prevention and Control [CDC], 2019), 
noted that, a total number of 1,658,716 new cases of cancer were reported in the United 
States alone. The new cases involved; 833,308 male, and 825,408 female patients. The 
overall incidence was reported as 436 per 100,000 people in which 471 per 100,000 were 
reported in males and 413 per 100,000 were reported in females (CDC, 2019). In view of 
these statistics, it can be fairly concluded that, cancer has a major grip on the lives of 
different populations, (African Americans, Caucasians, American Indians, etc.) the 
community and the entire country as the increase in mortality rate for cancer is growing 
daily, drastically affecting the US population as well as the entire world. This is a cause 
for concern in healthcare as researchers and healthcare professionals are working to 
educate the public about preventative measures to protect the lives of individuals who 
have not contracted cancer and also to cure or manage this disease to promote quality of 
life for individuals with cancer. 
Treatments such as Chemotherapy, Radiation, and Surgery, are the most 
recognized treatments in society today as most physicians and patients consider these 
their best treatment options and generally do not consider using CAM. (Klimant, Wright, 
Rubin, Seely, & Markman, 2018).  The use of traditional treatments for cancer have been 
proven effective, but also cause side effects. Pain, fatigue, nausea, and vomiting are 
among the commonly reported side effects in patients undergoing chemotherapy 
treatment (Ince & Yildirim, 2019). Despite the use of antiemetic drugs as a standard 
treatment to prevent nausea and vomiting before and after chemotherapy, it is reported 
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that, more than 60% and 45% of patients suffer nausea and vomiting respectively, 70% 
and 55% were reported to suffer from fatigue and pain respectively (Ince & Yildirim, 
2019).  The rates at which these major side effects occur in the lives of cancer patients is 
alarming, bringing importance to consideration of what can be done to reduce these 
burdensome side effects in the lives of cancer patients (Ince & Yildirim, 2019).  
 More than 15 million Americans living today have a history of cancer (ACS, 
2019). This disease takes a significant toll on the health of patients and their families and 
may also constitute a financial burden to the patients and their families as well. It was 
estimated that cancer patients paid nearly $4 billion out-of-pocket expenses for traditional 
treatment in 2014 (ACS, 2019). Cancer represents a significant proportion of total U.S 
health care spending. In 2014, $3.0 trillion was spent on healthcare in the US. 
Approximately $87.8 billion (2.93% of the total money spent on healthcare) was spent on 
cancer-related care (ACS, 2019).  
The purpose of this project was to observe whether IV C used as a treatment 
method can reduce the major side and adverse effects of chemotherapy and radiation 
treatments in cancer patients. In order to measure the effect of high dose IV C in cancer 
patients, the use of European Organization for Research and Treatment of cancer 
(EORTC QLQ-C30) questionnaire was used to determine side effects which included 
fatigue, pain, nausea, and vomiting during and after the completion of treatment in cancer 
patients. The questions for study were: 
1. In patients living with cancer, what is the effect of IV C treatment on side and 
adverse effects? 
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2. In patients living with cancer, what is the effect of IV C on quality of life 
(based on the EORTC QLQ-30 responses to questionnaire).  
Literature review 
The literature review for this project was carried out using different scholarly 
search engines through the University of Missouri-Saint Louis electronic library 
webpage. The scholarly websites includes Ovid MEDLINE, Psychological information 
(PsychINFO), CINHAL, and Public/publisher MEDLINE (PubMed). Databases articles 
searched range from 2015 to 2020 in which yielded 10 articles. The search was refined 
using the key terms to include; cancer and CAM treatments, IV C and cancer care, CAM 
care in cancer patients, side effects in cancer using the Boolean operators AND and OR. 
Inclusion criteria were adult cancer patients who were undergoing traditional treatment 
therapy, adult cancer patients between the ages range of 30 to 80 years of age, adult 
patients of different ethnicities diagnosed with cancer receiving treatment. Studies 
included treatment therapy that reduces side and adverse effects in cancer patients to 
enhance quality of life. Two articles were included in the literature review.  
The core quality of life (CQOL) in patients living with cancer who are being 
treated with traditional care alone (chemotherapy, radiation, etc.) may be complicated by 
side effects such as pain, fatigue, nausea and vomiting. The use of IV C is a safe 
supportive intervention to decrease inflammation in the patient and to improve side 
effects (Klimant, et al. 2018).  Studies that have already explored the effects of IV C in 
supportive care have design flaws such as small sample sizes. Length of the effect of an 
individual IV C treatment was unknown. Studies designed to test that factor could be 
useful in creating evidence-based guidelines for optimal or sustained improvement in 
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CQOL (Klimant, et al., 2018). There was limited high-quality clinical evidence on the 
safety and effectiveness of IV C. The existing evidence was preliminary and cannot be 
considered conclusive but was a suggestive of a good safety profile and potentially 
important antitumor activity; however, more rigorous evidence is needed to conclusively 
demonstrate these effects. IV C may improve the quality of life and symptom severity of 
patients with cancer, and several cases of cancer remission have been reported (Klimant, 
et al., 2018). High dose ascorbic acid may improve the anti-cancer action of 
chemotherapeutic agents, boost immune cell functioning, and inhibit angiogenesis 
(Mikirova, Casciari, & Hunninghake, 2019).  
In order to improve the quality of care in cancer patients, health care professionals 
need to understand how the disease and its traditional treatment affect cancer patients' 
health-related quality of life (HRQOL). The EORTC-C30 questionnaire was used to 
measure the HRQOL in cancer patients (Chantal, Coens, Ghislain, Zikos, Mirjam, 
Ringash, & Ediebah, 2015). The EORTC-C30 incorporates five functioning scales 
(Physical, role, cognitive, emotional, and social functioning) and three symptom scales 
(fatigue, pain, and nausea/vomiting) to measure the effectiveness of treatment regimens 
in cancer patients (Chantal, et al., 2015). The use of this questionnaire enhanced better 
understanding of treatment regimens for cancer patients and the need to provide a better 
care and treatment plans. 
In patients receiving chemotherapy treatments to manage cancer, it is reported 
that cancer-related fatigue, pain, nausea, and vomiting are the most common and 
debilitating side effects experienced by these patients (Peoples, Roscoe, Block, Heckler, 
Ryan, Mustian, & Dozier, 2017).  
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The prevalence and severity of these side effects are much higher in cancer patients 
undergoing chemotherapy than other therapies. It is reported that these side effects 
(fatigue, pain, nausea, and vomiting) interfere with physical, mental, social well-being, 
and often impact the patient’s ability to tolerate treatment. The side effects result in 
diminished quality of life and treatment discontinuation. Statistics showed that, 58% to 
94% of cancer patients reported these side effects during chemotherapy. The prevalence 
of these side effects are listed accordingly; fatigue-95%, pain-80%, nausea-75% and 
vomiting-72% (Peoples, et al., 2017). 
Chemotherapy drugs are calculated based on body surface area, which leads to 
large interpatient variability of drug clearance and marked interpatient differences in 
toxic effects (Foukakis, Minckwitz, Bengtsson, Brandberg, Wallberg, & Singer, 2016). 
Breast cancer is the most prevalent cancer in women and the standard chemotherapy 
treatment is usually cycles of fluorouracil and epirubicin-cyclophosphamide bi-weekly 
depending on the stages of the disease. Most patients undergoing the traditional treatment 
suffer side effects; nausea; 31%, vomiting; 46%, fatigue; 75%, pain 80%. Other side 
effects suffered by these patients include diarrhea; 40%, oral mucositis; 33%, motor 
neuropathy; 6%, and sensory neuropathy; 13% (Foukkais, et al., 2016). 
The administration of IV C in cancer patients has generated controversies and has 
not been supported by traditional treatment physicians and insurance companies. IV C 
therapy has been proven useful and beneficial for the control of major side effects in 
cancer patients receiving traditional treatment (Klimant, et al., 2018). Doses range from 
10 g to 25 g diluted in sterile water 150 ml to 500 ml given between 30 to 60 minutes. 
Reports showed that, diagnosed advanced cancer patients, including those undergoing 
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chemotherapy, who received doses of 12.5–100 g IV C given at a rate of 0.5–1.0 g per 
minute twice weekly for 4 weeks shows significant decreases in fatigue, nausea, 
vomiting, insomnia, and constipation after 2 weeks, and a reduction in pain after 4 weeks 
(Klimant, et al., 2018). The baseline mean global health status score of 44.6 improved to 
61.4 after 4 weeks of IV C treatment. Reports also indicated that, there was tremendous 
improvement in quality of life (QOL) as evidenced by EORTC-C30 in patients, and no 
adverse events were reported. The major issue with this therapy was financial constraint 
as patients undergoing this therapy paid bills out of pocket. The only side effect which 
was reported by 1% of patient receiving this therapy was thirst during treatment. This 
was controlled by drinking water during administration of treatment (Klimant, et al., 
2018). 
The Plan-Do-Study-Act cycle (PDSA) is a framework tool used by clinicians to 
measure the ongoing effort and assessing the quality of work delivered by healthcare 
professionals (Christoff, 2018). In the PDSA cycle during this project, the learning and 
improvement outcome was attained by testing two therapies using the process and 
outcome method. The outcome measure aids maximum understanding of how effective 
the IV C was by the result. The implementation of PDSA cycle utilized during this 










This was a quality improvement project. The study design in this project was 
observational cohort in which the researcher only observes the treatment result without 
participating nor intervening.  
Setting 
        The setting for this project was an outpatient treatment facility that specializes in 
the treatment of different diseases such as cancer with functional medicine and CAM to 
address the underlying cause of diseases at an urban, Midwestern Institute of Natural 
Health. This clinic is using a systems-oriented approach which included patient-centered 
care, scientific-based healthcare approach and integrating best medical practices to 
provide CAM treatments to patients. This organization employs 14 healthcare 
professionals who have provided care and treatments to over 150 patients for four years.  
Sample 
Participants included patients who are living with cancer between the age of 30-
80 years old, and currently undergoing cancer treatment. This study included a 
convenience sample of a total of 20 male and female adults between the ages of 30 – 80 
years. 
Procedures 
In November 2019, a team of stakeholders was formed that included a nurse 
practitioner, nurses, and medical assistant. There were several meetings regarding the 
discussion of information related to how the use of IV C was beneficial to cancer 
patients. A decision was made to utilize and implement the EORTC QLQ-C30 
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questionnaire to determine whether patients undergoing IV C therapy had side effects 
such as pain, fatigue, nausea and vomiting during and after treatment. The information 
will be used to develop educational training and educate clinicians performing IV C 
therapy. 
Approval Process 
 Initial approval was obtained from the Institute of Natural Health. Additional 
approvals were obtained from the doctoral committee, the university institute review 
board (IRB) and the final approval from the university graduate school. There was no risk 
associated with this project nor any ethical considerations.  
Data Collection and Analysis 
EORTC QLQ-30 was used for data collection (Appendix A). Data were collected 
via a retrospective medical record review from March 2020 to May 2020. The 
demographic data included age, race/ethnicity, and type of cancer. Data was coded and 
identified. Data included type of treatment therapy completed, and the result after the 
treatment. The data collected was stored with a password protected on a computer and a 
thumb drive by the primary investigator. The data collected was analyzed using 
descriptive and inferential statistics to answer questions, and make recommendations. 
The data was analyzed using Intellectus Statistics. Descriptive statistics and t-test were 
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Results 
A total number of twenty (N=20) charts of patients who underwent IV C, IV 
C/Traditional therapy for different types of cancer were reviewed. The age ranged from 
30-80 years. A majority of the patients were female (N=14, 70%), 9 of them were 
Caucasian, 4 of them were African American and 1 of them was Hispanic. The other 
patients were male (N=6, 30%) of which 3 were Caucasian and the other 3 were African 
American (Appendix B). 
Seven (N=7, 35%) of the charts for patients who underwent IV C/Traditional 
therapy reported little to no pain, no nausea/vomiting, and no fatigue on the therapy 
(m=0.85, SD=0.04), (Appendix B). The charts also revealed that, each patient reported 
improved quality of life. Thirteen (N=13, 65%) of the charts for patients who underwent 
IV C therapy reported little to no pain, no nausea/vomiting, and no fatigue (m=0.92, 
SD=0.02), (Appendix C) since they have been on this therapy. The charts also revealed 
that, these patients reported improved quality of life.  
Paired t-tests were calculated within each pair of measurements to examine the 
differences among the variables. Comparisons were conducted for all significant effects 
based on an alpha of 0.05. For the main effect of Treatment type, the mean of Treatment 
outcome for CAM (M = 0.92, SD = 0.02) was significantly larger than for 
CAM/Traditional (M = 0.85, SD = 0.04), p < .001. Although the sample size was small, 
the patients undergoing CAM/Traditional treatment reported a significant improvement 
as p <. 001 (Appendix C).  
 
INTRAVENOUS VITAMIN C IN CANCER PATIENTS 14 
 
Discussion 
The study was implemented within a 12-week period. Participants included 20 
cancer patients who underwent IV C, IV C/Traditional treatment for different types of 
cancer, have different comorbidities as stated on their chart (See appendix B) and were 
being assessed for side/adverse effects during the time frame.  
The 20 participants, (N=20, 100%) reported little to no pain, and none of them reported 
nausea/vomiting and or fatigue during their treatment process. This demonstrated that, IV 
C had positive effects in cancer patients. 
There was improved quality of life in the cancer patients as reported by the EORTC 
questionnaire and histogram table (Appendix D).  The results also suggested that, the use 
of EORTC is a very useful tool to measure the quality of life and or side/adverse effects 
in cancer patients undergoing a treatment therapy which is different from traditional 
therapy. The results of this quality improvement project also demonstrated that senior 
adult participants diagnosed with cancer reported improved quality of life with no 
side/adverse effects. IV C can be administered to adult patients who were diagnosed with 
cancer without any age limit (Appendix E).   
A limitation of this study was the smaller sample size. It is recommended that this study 
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Conclusion 
This quality improvement project was implemented to determine if the use of IV 
C therapy used for treatment in cancer patients would prevent the most frequently 
reported side/adverse effects reported in traditional treatment. It was noted that, IV C can 
be used for the treatment of cancer. Although a limitation in the study was a small sample 
size, the result showed that the use of IV C with and without traditional treatment 
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Appendix A 
Table 1.   Sample EORTC QLQ-C30 Questionnaire tool 
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Appendix B 
Table 2.  Demographics 
Gender, Age, Race/Ethnicity, Types of Cancer, Treatment type, Comorbidities 
 
 

























Variable M SD n SEm Min Max Skewness Kurtosis 
Treatment Outcome 
CAM 0.92 0.02 13 0.00 0.92 0.95 -0.14 -0.91 
CAM/Traditional 0.85 0.04 7 0.01 0.80 0.89 -0.55 -1.25 
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Appendix D 
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Appendix E 
Table. 5 
 
 
 
 
 
 
 
 
 
 
 
 
